GRDX GridAI Technologies Corp.

Nasdaq Pharmaceutical Preparations DE CIK: 0001604191
AI RATING
STRONG_SELL
88% Confidence

Investment Thesis

GridAI Technologies faces severe financial distress with only $403K in revenue while burning $1.7M in annual operating cash flow, leaving less than 18 months of cash runway at current burn rates. The company exhibits massive operating losses (net margin of -846,327%), negative free cash flow, and provides no evidence of viable commercialization or clear path to profitability in the pharmaceutical sector.

Strengths

  • + Conservative leverage with 0.23x Debt/Equity ratio
  • + Adequate current liquidity ratio of 2.62x providing short-term flexibility
  • + Reasonable asset base of $135.4M suggesting retained capital from prior financing

Risks

  • ! Critical cash runway of less than 18 months at current burn rate with only $2.5M cash on hand
  • ! Operating losses of $2.4M annually with no revenue traction to offset costs
  • ! Negative free cash flow of $1.8M indicates cash depletion, likely requiring dilutive equity financing or strategic alternatives

Key Metrics to Watch

Financial Metrics

Revenue
403.0
Net Income
-3.4M
EPS (Diluted)
$-2.28
Free Cash Flow
-1.8M
Total Assets
135.4M
Cash
2.5M

Profitability Ratios

Gross Margin N/A
Operating Margin -594,302.0%
Net Margin -846,327.5%
ROE -12.2%
ROA -2.5%
FCF Margin -446,324.8%

Balance Sheet & Liquidity

Current Ratio
2.62x
Quick Ratio
2.62x
Debt/Equity
0.23x
Debt/Assets
33.8%
Interest Coverage
-36.18x
Long-term Debt
6.4M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-10T18:00:22.703273 | Data as of: 2025-09-30 | Powered by Claude AI